High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections
- PMID: 23876395
- DOI: 10.1093/cid/cit471
High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections
Abstract
Background: Better understanding of complications and outcomes of adults hospitalized with respiratory syncytial virus (RSV) infection is necessary.
Methods: A retrospective cohort study was conducted on all adults (≥ 18 years) admitted to 3 acute care general hospitals in Hong Kong with virologically confirmed RSV infection during 2009-2011 (N = 607). Adults hospitalized for seasonal influenza during the period were used for comparison (n = 547). Both infections were prospectively diagnosed following a standard protocol. Independent reviews of chest radiographs were performed by radiologists. Main outcome measures were all-cause death, respiratory failure requiring ventilatory support, and hospitalization duration. Cox proportional hazards models were used for analyses.
Results: The mean age of RSV patients was 75 (SD, 16) years; 87% had underlying conditions. Lower respiratory and cardiovascular complications were diagnosed in 71.9% (pneumonia, 42.3%; acute bronchitis, 21.9%; chronic obstructive pulmonary disease/asthma exacerbation, 27.3%) and 14.3% of patients, respectively; 12.5% had bacterial superinfections. Supplemental oxygen and ventilatory support were required in 67.9% and 11.1%, respectively. Crude all-cause mortality was 9.1% and 11.9% within 30 days and 60 days, respectively; mean length of stay of survivors was 12 (SD, 13) days. Advanced age, radiographic pneumonia, requirement for ventilation, bacterial superinfection, and elevated urea level and white blood cell count were independently associated with poorer survival. Systemic corticosteroid use was associated with longer hospitalization and secondary infections. The overall outcomes of survival and length of stay were not significantly different from those in influenza.
Conclusions: RSV can cause severe lower respiratory complications in older adults, resulting in respiratory failure, prolonged hospitalization, and high mortality similar to seasonal influenza. Corticosteroids did not seem to improve outcomes. The unmet need for antiviral therapy and vaccination against RSV in adults should be promptly addressed.
Keywords: RSV; adults; hospitalization; lower respiratory tract infection; respiratory failure.
Comment in
-
Editorial commentary: respiratory syncytial virus: a global pathogen in an aging world.Clin Infect Dis. 2013 Oct;57(8):1078-80. doi: 10.1093/cid/cit473. Epub 2013 Jul 21. Clin Infect Dis. 2013. PMID: 23876396 No abstract available.
Similar articles
-
Respiratory syncytial virus infection in elderly and high-risk adults.N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. N Engl J Med. 2005. PMID: 15858184
-
Part 4. Interaction between air pollution and respiratory viruses: time-series study of daily mortality and hospital admissions in Hong Kong.Res Rep Health Eff Inst. 2010 Nov;(154):283-362. Res Rep Health Eff Inst. 2010. PMID: 21446214
-
Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults.Clin Infect Dis. 2019 Jul 2;69(2):197-203. doi: 10.1093/cid/ciy991. Clin Infect Dis. 2019. PMID: 30452608 Free PMC article.
-
Influenza and respiratory syncytial virus in the elderly.Expert Rev Vaccines. 2008 Mar;7(2):249-58. doi: 10.1586/14760584.7.2.249. Expert Rev Vaccines. 2008. PMID: 18324893 Review.
-
Respiratory syncytial virus infection in adults.Semin Respir Crit Care Med. 2007 Apr;28(2):171-81. doi: 10.1055/s-2007-976489. Semin Respir Crit Care Med. 2007. PMID: 17458771 Review.
Cited by
-
Health Technology Assessment del vaccino ricombinante adiuvato contro il virus respiratorio sinciziale (Arexvy®).J Prev Med Hyg. 2024 Jun 30;65(2 Suppl 1):E1-E159. doi: 10.15167/2421-4248/jpmh2024.65.2s1. eCollection 2024 Sep. J Prev Med Hyg. 2024. PMID: 39554593 Free PMC article. Italian. No abstract available.
-
Immediate post-discharge care among US adults hospitalized with respiratory syncytial virus infection.BMC Pulm Med. 2024 Oct 4;24(1):486. doi: 10.1186/s12890-024-03251-y. BMC Pulm Med. 2024. PMID: 39367363 Free PMC article.
-
Aging enhances pro-atrogenic gene expression and skeletal muscle loss following respiratory syncytial virus infection.Geroscience. 2024 Oct 2. doi: 10.1007/s11357-024-01370-2. Online ahead of print. Geroscience. 2024. PMID: 39354240
-
Adult patients with severe respiratory syncytial virus infections in the emergency department.Medicine (Baltimore). 2024 Sep 27;103(39):e39265. doi: 10.1097/MD.0000000000039265. Medicine (Baltimore). 2024. PMID: 39331940 Free PMC article.
-
Key Challenges to Understanding the Burden of Respiratory Syncytial Virus in Older Adults in Southeast Asia, the Middle East, and North Africa: An Expert Perspective.Adv Ther. 2024 Nov;41(11):4312-4334. doi: 10.1007/s12325-024-02954-2. Epub 2024 Sep 23. Adv Ther. 2024. PMID: 39312107 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
